Nafarelin is a synthetic ten-amino-acid peptide modeled on gonadotropin-releasing hormone (GnRH). It first stimulates and then suppresses the pituitary signals that drive estrogen and testosterone production. This guide covers its structure, mechanism, labeled uses, trials and warnings, with sources checked on November 17, 2026.
Quick answer: Nafarelin is a prescription GnRH agonist peptide sold as Synarel by Pfizer. Its label covers central precocious puberty in children and endometriosis in adult women. It has no boxed warning. Low-estrogen effects such as hot flashes are common, and the label warns of bone density loss in endometriosis treatment.
Vitrapep does not sell nafarelin; this page is a reference summary of published research and regulatory information.
What is nafarelin?
The Synarel label calls nafarelin acetate “a synthetic analog of the naturally occurring gonadotropin-releasing hormone (GnRH).” It describes the molecule as a decapeptide (Synarel label, 2025). A decapeptide is a chain of ten amino acids. GnRH is the brain hormone that tells the pituitary gland to release reproductive hormones.
The label’s chemical name spells out the chain. It starts with 5-oxo-L-prolyl, histidyl, tryptophyl, seryl and tyrosyl residues. The sixth residue is 3-(2-naphthyl)-D-alanine, a bulky, unnatural building block. Leucyl, arginyl, prolyl and glycinamide residues complete it. PubChem lists the formula as C66H83N17O13 and the molecular weight as 1,322.5 g/mol (PubChem CID 25077405). Our overview of peptide hormones explains the wider family.
Drugs@FDA lists the original approval of Synarel on February 13, 1990. The application is NDA 019886, held by Pfizer (Drugs@FDA). FDA’s orphan drug database lists a separate marketing approval for central precocious puberty on February 26, 1992, to Syntex (FDA orphan database).
Nafarelin: key facts
| Fact | Detail |
|---|---|
| Structure type | Synthetic linear decapeptide (ten amino acids), GnRH analog with a D-naphthylalanine at position 6 |
| Class | GnRH agonist |
| Molecular formula | C66H83N17O13 (free base) |
| Molecular weight | 1,322.5 g/mol |
| First FDA approval | February 13, 1990 (Synarel, NDA 019886); precocious puberty approval February 26, 1992 |
| Brand names (US) | Synarel |
How does nafarelin work?
Nafarelin acts on the same pituitary receptor as natural GnRH. The label explains that “at the onset of administration, nafarelin stimulates the release of the pituitary gonadotropins, LH and FSH.” LH and FSH are the hormones that signal the ovaries and testes.
That first surge does not last. With repeated exposure, the label says, the stimulatory effect on the pituitary is abolished. Gonadal steroid output then falls, which means less estrogen or testosterone (Synarel label, 2025). This “switch on, then shut down” pattern is shared by leuprolide and histrelin.
What is nafarelin approved for?
The Synarel label lists two indications:
- “treatment of central precocious puberty (CPP)” in children of both sexes; and
- “management of endometriosis, including pain relief and reduction of endometriotic lesions.”
Central precocious puberty is puberty that starts too early because the brain’s hormone signals switch on early. Endometriosis is a condition in which tissue like the uterine lining grows outside the uterus. For endometriosis, the label notes that experience is limited to adult women. It also says retreatment is not recommended because safety data are lacking (Synarel label, 2025).
What did the key trials show?
Endometriosis. A multicenter, double-blind human trial randomized 213 women with endometriosis confirmed by laparoscopy. It compared nafarelin with danazol, an older hormone drug. Doctors scored disease extent on laparoscopy before and after treatment.
More than 80 percent of patients in each group had less disease. Scores fell significantly in every group, with no significant difference between groups. The share of women with severe pain fell from about 40 percent to 5 to 10 percent. Of 149 women who tried to become pregnant afterward, 58 (39 percent) did (Henzl et al., 1988).
The side effect profiles differed. Danazol lowered HDL cholesterol and raised LDL cholesterol, changes not seen with nafarelin. Nafarelin users more often reported hot flashes and decreased libido. The authors concluded that “nafarelin is an effective agent for treating endometriosis.”
Central precocious puberty. An early human study tested nafarelin in 15 girls with gonadotropin-dependent precocious puberty. The authors reported that nafarelin reduced the hormone measures they tracked. They concluded that it could treat the condition in girls (Lin et al., 1986). The label summarizes its larger pediatric human trials. Breast development “was arrested or regressed in 82% of girls.” Genital development was arrested or regressed in 100% of boys. Among 69 children followed for a year after stopping, suppression reversed in all of them (Synarel label, 2025).
What side effects does the label list?
The Synarel label has no boxed warning. In 155 children treated for central precocious puberty, the most frequent adverse events were:
- acne (10%);
- temporary breast enlargement (8%);
- vaginal bleeding (8%);
- emotional lability (6%);
- a temporary increase in pubic hair (5%); and
- rhinitis (5%).
In 1,509 adults in endometriosis trials, the most common reactions came from low estrogen. They include hot flashes, headaches, emotional lability, decreased libido, vaginal dryness, acne, muscle pain and reduced breast size. The label adds that the low-estrogen state causes “a small loss in bone density,” some of which “may not be reversible.”
Warnings cover psychiatric events, convulsions and pseudotumor cerebri in children, and severe skin reactions. In endometriosis, the label warns that depression may occur or worsen. Contraindications include pregnancy, breastfeeding, undiagnosed abnormal vaginal bleeding and allergy to GnRH agonists (Synarel label, 2025).
What is nafarelin’s regulatory status, and how is it used in research?
Synarel is a prescription drug in the United States. Drugs@FDA lists its marketing status as prescription, with Pfizer as the holder (Drugs@FDA). DailyMed lists one Synarel label, last revised in November 2025.
Recent registry entries for nafarelin focus on fertility treatment. A phase 4 randomized trial at Fundacion Dexeus is comparing nafarelin with triptorelin to trigger final egg maturation. It plans to enroll 154 women, and its primary outcome is the number of mature eggs retrieved (NCT06763926). A phase 3 trial in Paris is testing nafarelin for luteal phase support after a triptorelin trigger (NCT06150703). Both are listed as recruiting, and neither is an approved use.
Frequently asked questions about nafarelin
Is nafarelin a peptide?
Yes. It is a synthetic decapeptide, a chain of ten amino acids modeled on natural GnRH.
When was nafarelin approved?
Drugs@FDA lists the original approval of Synarel on February 13, 1990.
What conditions is Synarel approved for?
The label covers central precocious puberty in children and endometriosis in adult women.
How does nafarelin compare with danazol?
In a 213-patient trial, both reduced endometriosis to a similar degree. Danazol worsened blood cholesterol markers, while nafarelin caused more hot flashes and decreased libido.
Does nafarelin affect bone density?
Yes. The label says its low-estrogen effect causes a small loss in bone density, some of which may not be reversible.
What to know now
- Structure: synthetic GnRH decapeptide with a D-naphthylalanine at position 6; 1,322.5 g/mol.
- Approval: Synarel, February 13, 1990; prescription only.
- Mechanism: GnRH agonist; brief stimulation, then pituitary suppression.
- Label: central precocious puberty and endometriosis.
- Evidence: similar to danazol in a 213-patient endometriosis trial; breast development halted or regressed in 82% of girls with CPP.
- Safety: no boxed warning; low-estrogen effects and some bone loss.
What we’re watching
Results from the two recruiting fertility trials, NCT06763926 (primary completion estimated January 2028) and NCT06150703. Further Synarel label revisions on DailyMed, last revised in November 2025. Related guides: histrelin, leuprolide and gonadorelin.